Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a first, scientists used computer simulations to identify the vaccines most likely to be effective against respiratory syncytial virus (RSV), the most common cause of infant severe pneumonia worldwide.

CTMGH logo for News

Although there is no vaccine yet available for RSV, a viral infection that annually kills up to 200,000 children under five globally, a study published today in Vaccine suggested that the most effective vaccine would be one that stops RSV from spreading in the general population rather than one that completely prevented disease in RSV-infected individuals.

“This approach radically alters the way we decide which promising vaccine to develop. Choosing which new vaccines to develop from many possible candidates is an expensive process. As using mathematical modelling helps do that more efficiently, we expect that the pharmaceutical industry will use this approach more and more in the future,” says study leader Prof. Lisa White, of the University of Oxford, and Head of Mathematical and Economic MODelling (MAEMOD) at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand.

“When we used mathematical modelling simulations to find the best choices among candidate anti-RSV vaccines, we were surprised to find that the most effective vaccines would not provide solid immunity to reinfection but would reduce the infectiousness of infected individuals, thereby protecting the community at large by reducing the amount of virus in circulation,” explained study co-author Dr Wirichada Pan-Ngum, Deputy Head of Mathematical Modelling at MORU.

The study, a collaboration between researchers linked to the universities of Oxford, Warwick and Manchester in the UK, Kenya and Mahidol University, Thailand, in partnership with global vaccine developer GSK-Biologicals, Belgium, examined which properties RSV vaccines under development would need to have to be most effective in preventing RSV in young children.

The researchers were linked by a new network of mathematical modelers based in the Tropics (TDMODNET). The network is a highly innovative environment which nurtures talented mathematicians from Asia and Africa. “We have proven that true world-class innovation can come from a South-South collaboration of scientists,” said Dr Tim Kinyanjui, study co-author formerly in KEMRI and now in the School of Mathematics, University of Manchester, and Manchester M13 9PL, United Kingdom.

Unlike vaccines that currently control common childhood diseases, new vaccines must target diseases with complex and poorly understood immunity. These diseases nevertheless cause a huge amount of suffering and death.

“RSV is the most important cause of infant severe lower respiratory tract disease worldwide, estimated to be responsible for 3 million hospital admissions annually. Occurring in seasonal outbreaks, RSV causes an inflammatory immune response and that constricts airflow, with many children developing pneumonia or bronchiolitis,” says study co-author and major RSV researcher Prof. James Nokes, of the University of Warwick and Kenya Medical Research Institute (KEMRI)/Wellcome Trust in Kilifi, Kenya.

“New vaccines demand new development pathways and this research is the first to use computer simulation to support the process going a long way to demonstrate that our researchers are in the lead in thinking of innovative ways of improving the effectiveness of our vaccines,” Said Dr. Gerald Mkoji the Ag. Director of KEMRI

Similar stories

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality